Exploring new drugs can be considered from the mechanism of PD, such as targeting α-synuclein aggregation, ferroptosis and OS etc. The related drugs currently under development have not shown good effects, and may still require a long period of exploration. This evidence concerns the gene SNCA and Parkinson disease.